| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.08.25 | CARGO Therapeutics, Inc. - 15-12G, Securities registration termination | 2 | SEC Filings | ||
| CARGO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.07.25 | Cargo Therapeutics, Inc.: CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right | 343 | GlobeNewswire (Europe) | SAN CARLOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. ("CARGO" or the "Company") (NASDAQ: CRGX), a biotechnology company that has focused on developing CAR T-cell therapies... ► Artikel lesen | |
| 19.03.25 | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | 1.388 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| 18.03.25 | Cargo Therapeutics, Inc.: CARGO Therapeutics Provides Corporate Update | 694 | GlobeNewswire (Europe) | - Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,068 | +0,70 % | Evotec Aktie: Der dicke Knoten könnte bald platzen - einsteigen? | Bei der Evotec Aktie bleibt es das bekannte Bild: seit November 2024 (!) scheitern regelmäßig die Versuche der Biotech-Aktie, sich stabil über der 200-Tage-Linie zu etablieren. Sieben Breakphasen über... ► Artikel lesen | |
| MEDIGENE | 0,040 | -10,67 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 41,350 | -3,62 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| VALNEVA | 4,658 | +6,88 % | Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom | Lyon (France), February 13, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's... ► Artikel lesen | |
| STRYKER | 311,60 | +1,14 % | Stryker Launches T2 Alpha Humerus Nailing System for Fracture Care | ||
| ILLUMINA | 98,58 | -0,06 % | Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips | ||
| CRISPR THERAPEUTICS | 45,800 | +2,69 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 663,60 | -2,01 % | Regeneron Pharmaceuticals, Inc.: Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy | 36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies... ► Artikel lesen | |
| BRAIN BIOTECH | 2,240 | +0,45 % | Brain Biotech: Kursziel der Aktie wird gestutzt | Die Analysten der Deutschen Bank bezeichnen die jüngsten Zahlen von Brain Biotech als Enttäuschung. 2024/2025 sinkt der Umsatz von 54,6 Millionen Euro auf 49,6 Millionen Euro. Für das neue Geschäftsjahr... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,320 | -6,38 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,105 | +7,83 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen | |
| BAVARIAN NORDIC | 25,880 | +2,17 % | Bavarian Nordic A/S: Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026 | Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.2026 guidance reflects continued growth in Travel Health... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | +2,64 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| TEMPUS AI | 44,600 | +2,29 % | Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel | ||
| BIO-GATE | 0,600 | +2,56 % | Bio-Gate: EBITDA verbessert | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) mit 3,44 Mio. Euro einen leicht unter Vorjahr... ► Artikel lesen |